2023. Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies. SKIN The Journal of Cutaneous Medicine. 7, 6 (Nov. 2023), s294. DOI:https://doi.org/10.25251/skin.7.supp.294.